Contraindications for Telehealth Ketamine

Contraindications are conditions or circumstances that make a treatment inadvisable or unsafe. For at-home telehealth ketamine, the contraindication list is more extensive than for in-person IV ketamine under clinical supervision—because the at-home setting reduces the ability to respond to adverse events. For patients who do not meet candidacy criteria, our guide on when in-person treatment is required explains the alternatives.

This guide provides a comprehensive reference for the contraindications that responsible telehealth ketamine programs apply.

Absolute Contraindications

Absolute contraindications are conditions in which telehealth ketamine must not be administered, regardless of other clinical circumstances.

Active Psychosis or Schizophrenia Spectrum Disorder

Ketamine's NMDA receptor antagonism can exacerbate psychotic symptoms. Patients with active hallucinations, delusions, or disorganized thinking are at high risk of severe adverse psychiatric events. This is an absolute contraindication across all settings.

Uncontrolled Hypertension

Ketamine reliably and meaningfully elevates blood pressure. In patients with already-elevated blood pressure that is not controlled with medication, ketamine administration can produce hypertensive crises. A typical threshold: systolic BP > 160-180 mmHg on appropriate medications. Patients with uncontrolled severe hypertension should not receive ketamine.

Known Allergy or Hypersensitivity to Ketamine

Allergic reactions to ketamine are rare but have been reported. A confirmed allergy is an absolute contraindication.

Current Active Ketamine or Dissociative Substance Misuse

Prescribing ketamine to a patient who is currently misusing ketamine or other dissociatives (PCP, DXM) would compound existing harms and is not clinically appropriate.

Pregnancy

Ketamine crosses the placental barrier. Adequate safety data in human pregnancy is not available. Ketamine is classified Pregnancy Category C. In the absence of safety data and given the non-emergency nature of psychiatric ketamine, use in pregnancy is contraindicated.

Active Severe Unstable Mania

Ketamine can trigger mania in susceptible patients. Active, unstabilized manic episodes are a contraindication to ketamine administration.

Strong Relative Contraindications

Strong relative contraindications are conditions that generally preclude at-home telehealth ketamine but may be manageable in specialized in-person settings.

Active Suicidal Ideation with Intent or Plan

While ketamine has demonstrated anti-suicidal properties, patients with active suicidal ideation require a higher level of care than at-home telehealth provides. The reduced monitoring of the at-home setting is incompatible with the safety requirements for actively suicidal patients.

Recent Psychiatric Hospitalization (< 3-6 months)

Recent hospitalization signals a level of psychiatric instability that at-home treatment is not designed to manage. These patients should have re-established outpatient stability before at-home telehealth is considered.

Significant Cardiovascular Disease

Includes: recent myocardial infarction (within 6 months), significant cardiac arrhythmias, moderate-to-severe heart failure, unstable angina. These conditions require cardiac monitoring and response capability that at-home settings cannot provide.

Significant Hepatic Impairment

Child-Pugh Class B or C liver disease significantly alters ketamine metabolism. Unpredictable pharmacokinetics in severe liver disease make dosing unreliable and at-home administration unsafe.

Active Moderate-Severe Alcohol Use Disorder

Combines both pharmacological (CNS depressant interaction, impaired metabolism) and clinical (unreliable self-administration, inability to ensure sobriety before sessions) safety concerns.

Thyrotoxicosis (Uncontrolled Hyperthyroidism)

Thyroid hormone excess potentiates ketamine's cardiovascular effects. Uncontrolled hyperthyroidism is a contraindication.

Drug Interactions and Relative Contraindications

MAO Inhibitors (MAOIs)

Phenelzine, tranylcypromine, selegiline, and other MAOIs interact with ketamine. The combination can cause severe hypertension or CNS toxicity. A washout period of at least 2 weeks (longer for some MAOIs) is required before starting ketamine.

High-Dose Stimulants

Patients taking high doses of stimulant medications (amphetamine salts, methylphenidate) have higher baseline cardiovascular stimulation. Concomitant ketamine use further elevates blood pressure and heart rate. This does not necessarily preclude ketamine, but requires careful dose titration and enhanced cardiovascular monitoring.

High-Dose Benzodiazepines

Benzodiazepines are not dangerous in combination with ketamine and are sometimes used to manage anxiety during ketamine sessions. However, high-dose benzodiazepine use can blunt ketamine's therapeutic effects and may suggest underlying anxiety severity that warrants careful clinical evaluation.

Opioid Analgesics

Ketamine and opioids are sometimes deliberately combined for analgesia (ketamine can reduce opioid requirements). However, the combination in the at-home setting requires careful management. Patients on significant opioid doses should have provider review of the interaction before starting ketamine.

Lithium

The combination of lithium and ketamine has been associated with prolonged or unpredictable effects in case reports. Patients on lithium should proceed cautiously with careful monitoring, particularly regarding signs of toxicity.

Non-Medical Contraindications (At-Home Specific)

Beyond medical and psychiatric contraindications, the at-home model has specific practical contraindications:

Unsafe Home Environment

Domestic violence, significant household instability, or inability to ensure privacy and safety during sessions are contraindications to at-home treatment specifically. These patients may be candidates for in-person treatment.

No Available Sitter (First Sessions)

Patients who cannot arrange for a sober adult sitter for the first several sessions lack a critical safety element. Most responsible programs will not approve sessions without sitter confirmation. Learn more about the sitter role in our support systems guide.

Unreliable Internet or Device Access

Adequate telehealth connectivity is a practical requirement. Patients who cannot reliably maintain video contact with providers during sessions lack a key monitoring component.

Discussing Contraindications With Your Provider

If you have any of the conditions listed above, discuss them openly with your telehealth ketamine provider. Do not conceal relevant medical history in order to gain approval—doing so removes the provider's ability to protect your safety and shifts the risk entirely to you.

If you have a relative contraindication, the appropriate response is a careful clinical conversation—not automatic exclusion, and not self-authorization to proceed. The provider's assessment of your specific situation, risk factors, and available safeguards should guide the decision. For more on how providers evaluate candidates, see our patient selection guide.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service